You are currently viewing the abstract.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Abstract
Genomic profiling provides insights into drug evaluation for diseases without defined molecular mechanisms or cellular assays. Levy provides a brief background in the development of microarray analysis and discussion of the application of this technique to pharmacogenomics. Highlighted is the microarray analysis of primary human neurons treated with antidepressants, antipsychotics, or opioid receptor agonists, demonstrating that these classes of drugs can be properly categorized by using two different statistical analysis methods: classification tree and random forest. Not only is microarray analysis valuable for drug evaluation and leading candidate development, but the genes identified as markers for the various drug classifications point to new directions for research into the underlying pathways responsible for human diseases, such as depression and psychosis.
